1. Clark W.H., Jr., Elder D.E., Guerry Dt, Epstein M.N., Greene M.H., Van Horn M.: A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984, 15(12): 1147 - 1165.

2. Plonka P.M., Passeron T., Brenner M., Tobin D.J., Shibahara S., Thomas A., Slominski A., Kadekaro A.L., Hershkovitz D., Peters E. et al: What are melanocytes really doing all day long...? Exp Dermatol 2009, 18(9): 799 - 819.

3. Fitzpatrick T.B.: The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988, 124(6): 869 - 871.

4. Dubin N., Pasternack B.S., Moseson M.: Simultaneous assessment of risk factors for malignant melanoma and non-melanoma skin lesions, with emphasis on sun exposure and related variables. Int J Epidemiol 1990, 19(4): 811 - 819.

5. Carli P., Biggeri A., Nardini P., De Giorgi V., Giannotti B.: Sun exposure and large numbers of common and atypical melanocytic naevi: an analytical study in a southern European population. Br J Dermatol 1998, 138(3): 422 - 425.

6. Elwood J.M., Koh H.K.: Etiology, epidemiology, risk factors, and public health issues of melanoma. Curr Opin Oncol 1994, 6(2): 179 - 187.

7. Anna B., Blazej Z., Jacqueline G., Andrew C.J., Jeffrey R., Andrzej S.: Mechanism of UV-related carcinogenesis and its contribution to nevi/melanoma. Expert Rev Dermatol 2007, 2(4): 451 - 469.

8. Lotze T.M., Dallal R.M., Kirkwood J.M., Flickinger J.C.: Cutaneous Melanoma. In: Cancer: Principles and Practice of Oncology 6th edition. edn. Edited by Devita V.T., Hellman S., Rosenberg S.A.: Lippincott Williams & Wilkins.

9. Whiteman D.C., Pavan W.J., Bastian B.C.: The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011, 24(5): 879 - 897.

10. Mihajlovic M., Vlajkovic S., Jovanovic P., Stefanovic V.: Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol 2012, 5(8): 739 - 753.

11. Mahendraraj K., Lau C.S., Lee I., Chamberlain R.S.: Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7,516 patients from the Surveillance, Epidemiology, and End Results database (1973 - 2012). Clin Ophthalmol 2016, 10: 2113 - 2119.

12. Seddon J., Gragoudas E., Egan K., Polivogianis L., Finn S., Albert D.: Standardized data collection and coding in eye disease epidemiology: the Uveal Melanoma Data System. Ophthalmic Surg 1991, 22(3): 127 - 136.

13. Каприн А.Д., Старинский В.В., Петрова Г.В. (eds.): Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России; 2018.

14. Каприн А.Д., Старинский В.В., Петрова Г.В. (eds.): Состояние онкологической помощи населению России в 2018 году. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России; 2019.

15. International Statistical Classification of Diseases and Related Health Problems 10th Revision [http://apps.who.int/classifications/icd10/browse/2016/en]

16. Каприн А.Д., Старинский В.В., Петрова Г.В. (eds.): Состояние онкологической помощи населению России в 2017 году. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России; 2018.

17. Gershenwald J., Scolyer R., Hess K., al. e: Melanoma of the skin. In: AJCC Cancer Staging Manual 8th ed. edn. Edited by Amin M., Edge S., Greene F., al. e. New York: Springer International Publishing; 2017: 563 - 585.

18. Barr R.G.: Foreword to the Second Set of WFUMB Guidelines and Recommendations on the Clinical Use of Ultrasound Elastography. Ultrasound Med Biol 2017, 43(1): 1 - 3.

19. Синельников И.Е., Барышников К.А., Демидов Л.В.: КЛИНИЧЕСКАЯ ДИАГНОСТИКА МЕЛАНОМЫ КОЖИ. Вестник ФГБУ "РОНЦ им Н.Н. Блохина" 2017, 28(1-2): 68 - 73.

20. Grob J.J., Bonerandi J.J.: The "ugly duckling" sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol 1998, 134(1): 103 - 104.

21. Garbe C., Peris K., Hauschild A., Saiag P., Middleton M., Bastholt L., Grob J.J., Malvehy J., Newton-Bishop J., Stratigos A.J. et al: Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. Eur J Cancer 2016, 63: 201 - 217.

22. Coit D.G., Thompson J.A., Albertini M., Algazi A., Andtbacka R., Bichakjian C., Carson W.E., 3rd, Daniels G.A., DiMaio D., Fields R.C. et al: NCCN Clinical Practice Guidelines in Oncology. Melanoma. Version 3.2018. In.: National Comprehensive Cancer Network, Inc; 2018: 172.

23. Rat C., Grimault C., Quereux G., Dagorne M., Gaultier A., Khammari A., Dreno B., Nguyen J.M.: Proposal for an annual skin examination by a general practitioner for patients at high risk for melanoma: a French cohort study. BMJ open 2015, 5(7): e007471.

24. P DES, Valiante M., Silipo V.: Familial melanoma and multiple primary melanoma. G Ital Dermatol Venereol 2017.

25. Grange F.: [Multiple primary melanoma and familial melanoma. Risk evaluation and screening tests. How to evaluate the risk of developing a second melanoma? In what family? Should screening methods be implemented? Which ones and why?]. Ann Dermatol Venereol 1995, 122(5): 365 - 371.

26. Claeson M., Holmstrom P., Hallberg S., Gillstedt M., Gonzalez H., Wennberg A.M., Paoli J.: Multiple Primary Melanomas: A Common Occurrence in Western Sweden. Acta Derm Venereol 2016.

27. Moore M.M., Geller A.C., Warton E.M., Schwalbe J., Asgari M.M.: Multiple primary melanomas among 16,570 patients with melanoma diagnosed at Kaiser Permanente Northern California, 1996 to 2011. J Am Acad Dermatol 2015, 73(4): 630 - 636.

28. De Giorgi V., Savarese I., D'Errico A., Gori A., Papi F., Colombino M., Sini M.C., Grazzini M., Stanganelli I., Rossari S. et al: Epidemiological features and prognostic parameters of multiple primary melanomas in CDKN2A-mutations patients. Pigment Cell Melanoma Res 2015, 28(6): 747 - 751.

29. Watts C.G., Dieng M., Morton R.L., Mann G.J., Menzies S.W., Cust A.E.: Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review. Br J Dermatol 2015, 172(1): 33 - 47.

30. Dinnes J., Deeks J.J., Grainge M.J., Chuchu N., Ferrante di Ruffano L., Matin R.N., Thomson D.R., Wong K.Y., Aldridge R.B., Abbott R. et al: Visual inspection for diagnosing cutaneous melanoma in adults. Cochrane Database of Systematic Reviews 2018(12).

31. Stapleton J.L., Turrisi R., Mallett K.A., Robinson J.K.: Correspondence between pigmented lesions identified by melanoma patients trained to perform partner-assisted skin self-examination and dermatological examination. Cancer Epidemiol Biomarkers Prev 2015, 24(8): 1247 - 1253.

32. Duarte A.F., da Costa-Pereira A., Del-Marmol V., Correia O.: Are General Physicians Prepared for Struggling Skin Cancer?-Cross-Sectional Study. J Cancer Educ 2016.

33. Ilyas M., Costello C.M., Zhang N., Sharma A.: The role of the ugly duckling sign in patient education. J Am Acad Dermatol 2017, 77(6): 1088 - 1095.

34. Dinnes J., Deeks J.J., Grainge M.J., Chuchu N., Ferrante di Ruffano L., Matin R.N., Thomson D.R., Wong K.Y., Aldridge R.B., Abbott R. et al: Visual inspection for diagnosing cutaneous melanoma in adults. The Cochrane database of systematic reviews 2018, 12: Cd013194.

35. Chia A., Trevena L.: A Systematic Review of Training to Improve Melanoma Diagnostic Skills in General Practitioners. J Cancer Educ 2016, 31(4): 730 - 735.

36. Castro L.G., Messina M.C., Loureiro W., Macarenco R.S., Duprat Neto J.P., Di Giacomo T.H., Bittencourt F.V., Bakos R.M., Serpa S.S., Stolf H.O. et al: Guidelines of the Brazilian Dermatology Society for diagnosis, treatment and follow up of primary cutaneous melanoma--Part I. An Bras Dermatol 2015, 90(6): 851 - 861.

37. Dinnes J., Deeks J.J., Chuchu N., Ferrante di Ruffano L., Matin R.N., Thomson D.R., Wong K.Y., Aldridge R.B., Abbott R., Fawzy M. et al: Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults. The Cochrane database of systematic reviews 2018, 12: Cd011902.

38. Ferrante di Ruffano L., Takwoingi Y., Dinnes J., Chuchu N., Bayliss S.E., Davenport C., Matin R.N., Godfrey K., O'Sullivan C., Gulati A. et al: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults. The Cochrane database of systematic reviews 2018, 12: CD013186.

39. Menzies S.W., Ingvar C., McCarthy W.H.: A sensitivity and specificity analysis of the surface microscopy features of invasive melanoma. Melanoma Res 1996, 6(1): 55 - 62.

40. Argenziano G., Longo C., Cameron A., Cavicchini S., Gourhant J.Y., Lallas A., McColl I., Rosendahl C., Thomas L., Tiodorovic-Zivkovic D. et al: Blue-black rule: a simple dermoscopic clue to recognize pigmented nodular melanoma. Br J Dermatol 2011, 165(6): 1251 - 1255.

41. Lallas A., Longo C., Manfredini M., Benati E., Babino G., Chinazzo C., Apalla Z., Papageorgiou C., Moscarella E., Kyrgidis A. et al: Accuracy of Dermoscopic Criteria for the Diagnosis of Melanoma In Situ. JAMA Dermatol 2018, 154(4): 414 - 419.

42. Longo C., Piana S., Marghoob A., Cavicchini S., Rubegni P., Cota C., Ferrara G., Cesinaro A.M., Baade A., Bencini P.L. et al: Morphological features of naevoid melanoma: results of a multicentre study of the International Dermoscopy Society. Br J Dermatol 2015, 172(4): 961 - 967.

43. Menzies S.W., Kreusch J., Byth K., Pizzichetta M.A., Marghoob A., Braun R., Malvehy J., Puig S., Argenziano G., Zalaudek I. et al: Dermoscopic evaluation of amelanotic and hypomelanotic melanoma. Arch Dermatol 2008, 144(9): 1120 - 1127.

44. Moloney F.J., Menzies S.W.: Key points in the dermoscopic diagnosis of hypomelanotic melanoma and nodular melanoma. J Dermatol 2011, 38(1): 10 - 15.

45. Carapeba MOL, Alves Pineze M., Nai G.A.: Is dermoscopy a good tool for the diagnosis of lentigo maligna and lentigo maligna melanoma? A meta-analysis. Clin Cosmet Investig Dermatol 2019, 12: 403 - 414.

46. Schiffner R., Schiffner-Rohe J., Vogt T., Landthaler M., Wlotzke U., Cognetta A.B., Stolz W.: Improvement of early recognition of lentigo maligna using dermatoscopy. J Am Acad Dermatol 2000, 42(1 Pt 1): 25 - 32.

47. Koga H., Saida T.: Revised 3-step dermoscopic algorithm for the management of acral melanocytic lesions. Arch Dermatol 2011, 147(6): 741 - 743.

48. Koga H., Saida T., Uhara H.: Key point in dermoscopic differentiation between early nail apparatus melanoma and benign longitudinal melanonychia. J Dermatol 2011, 38(1): 45 - 52.

49. Phan A., Dalle S., Touzet S., Ronger-Savle S., Balme B., Thomas L.: Dermoscopic features of acral lentiginous melanoma in a large series of 110 cases in a white population. Br J Dermatol 2010, 162(4): 765 - 771.

50. Adler N.R., Kelly J.W., Guitera P., Menzies S.W., Chamberlain A.J., Fishburn P., Button-Sloan A.E., Heal C., Soyer H.P., Thompson J.F.: Methods of melanoma detection and of skin monitoring for individuals at high risk of melanoma: new Australian clinical practice. Med J Aust 2019, 210(1): 41 - 47.

51. Tschandl P., Hofmann L., Fink C, Kittler H., Haenssle H.A.: Melanomas vs. nevi in high-risk patients under long-term monitoring with digital dermatoscopy: do melanomas and nevi already differ at baseline? J Eur Acad Dermatol Venereol 2017, 31(6): 972 - 977.

52. Watts C.G., Wortley S., Norris S., Menzies S.W., Guitera P., Askie L., Mann G.J., Morton R.L., Cust A.E.: A National Budget Impact Analysis of a Specialised Surveillance Programme for Individuals at Very High Risk of Melanoma in Australia. Appl Health Econ Health Policy 2018, 16(2): 235 - 242.

53. Ferrante di Ruffano L., Takwoingi Y., Dinnes J., Chuchu N., Bayliss S.E., Davenport C., Matin R.N., Godfrey K., O'Sullivan C., Gulati A. et al: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults. The Cochrane database of systematic reviews 2018, 12: Cd013186.

54. Giavedoni P., Ririe M., Carrera C., Puig S., Malvehy J.: Familial Melanoma Associated with Li-Fraumeni Syndrome and Atypical Mole Syndrome: Total-body Digital Photography, Dermoscopy and Confocal Microscopy. Acta Derm Venereol 2017, 97(6): 720 - 723.

55. Kittler H., Guitera P., Riedl E., Avramidis M., Teban L., Fiebiger M., Weger R.A., Dawid M., Menzies S.: Identification of clinically featureless incipient melanoma using sequential dermoscopy imaging. Arch Dermatol 2006, 142(9): 1113 - 1119.

56. Rinner C., Tschandl P., Sinz C., Kittler H.: Long-term evaluation of the efficacy of digital dermatoscopy monitoring at a tertiary referral center. J Dtsch Dermatol Ges 2017, 15(5): 517 - 522.

57. Robinson J.K., Nickoloff B.J.: Digital epiluminescence microscopy monitoring of high-risk patients. Arch Dermatol 2004, 140(1): 49 - 56.

58. Berk-Krauss J., Polsky D., Stein J.A.: Mole Mapping for Management of Pigmented Skin Lesions. Dermatol Clin 2017, 35(4): 439 - 445.

59. Truong A., Strazzulla L., March J., Boucher K.M., Nelson K.C., Kim C.C., Grossman D.: Reduction in nevus biopsies in patients monitored by total body photography. J Am Acad Dermatol 2016, 75(1): 135 - 143 e135.

60. Inskip M., Magee J., Weedon D., Rosendahl C.: When algorithms falter: a case report of a very small melanoma excised due to the dermatoscopic "ugly duckling" sign. Dermatol Pract Concept 2013, 3(2): 59 - 62.

61. Akay B.N., Okcu Heper A., Clark S., Erdem C., Rosendahl C.O., Kittler H.: Dermatoscopy of a melanoma less than one millimeter in diameter. Int J Dermatol 2017, 56(12): 1498 - 1499.

62. Bafounta M.L., Beauchet A., Chagnon S., Saiag P.: Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis. Lancet Oncol 2004, 5(11): 673 - 680.

63. Farberg A.S., Rigel D.S.: A comparison of current practice patterns of US dermatologists versus published guidelines for the biopsy, initial management, and follow up of patients with primary cutaneous melanoma. J Am Acad Dermatol 2016, 75(6): 1193 - 1197 e1191.

64. Weinstock M.A., Lott J.P., Wang Q., Titus L.J., Onega T., Nelson H.D., Pearson L., Piepkorn M., Elmore J.G., Tosteson A.N.: Skin Biopsy Utilization and Melanoma Incidence among Medicare Beneficiaries. Br J Dermatol 2016.

65. Rayess H.M., Gupta A., Svider P.F., Raza S.N., Shkoukani M., Zuliani G.F., Carron M.A.: A critical analysis of melanoma malpractice litigation: Should we biopsy everything? Laryngoscope 2017, 127(1): 134 - 139.

66. Moscarella E., Argenziano G., Moreno C., Piana S., Lallas A., Lombardi M., Longo C., Ferrara G.: Intralesional (incision) biopsy for melanoma diagnosis: the rules and the exception to the rules. G Ital Dermatol Venereol 2016.

67. Bolshinsky V., Lin M.J., Serpell J., Leung M., Wolfe R., McLean C., Kelly J.W.: Frequency of residual melanoma in wide local excision (WLE) specimens after complete excisional biopsy. J Am Acad Dermatol 2016, 74(1): 102 - 107.

68. Luk P.P., Vilain R., Crainic O., McCarthy S.W., Thompson J.F., Scolyer R.A.: Punch biopsy of melanoma causing tumour cell implantation: another peril of utilising partial biopsies for melanocytic tumours. Australas J Dermatol 2015, 56(3): 227 - 231.

69. Soltani-Arabshahi R., Sweeney C., Jones B., Florell S.R., Hu N., Grossman D.: Predictive value of biopsy specimens suspicious for melanoma: support for 6-mm criterion in the ABCD rule. J Am Acad Dermatol 2015, 72(3): 412 - 418.

70. Mills J.K., White I., Diggs B., Fortino J., Vetto J.T.: Effect of biopsy type on outcomes in the treatment of primary cutaneous melanoma. Am J Surg 2013, 205(5): 585 - 590; discussion 590.

71. de Lecea M.V., Palomares T., Al Kassam D., Cavia M., Geh J.L., de Llano P., Muniz P., Armesto D., Martinez-Indart L., Alonso-Varona A.: Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B. J Eur Acad Dermatol Venereol 2016.

72. Nikolin B., Djan I., Trifunovic J., Dugandzija T., Novkovic D., Djan V., Vucinic N.: MIA, S100 and LDH as important predictors of overall survival of patients with stage IIb and IIc melanoma. J BUON 2016, 21(3): 691 - 697.

73. Wevers K.P., Kruijff S., Speijers M.J., Bastiaannet E., Muller Kobold A.C., Hoekstra H.J.: S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma. Ann Surg Oncol 2013, 20(8): 2772 - 2779.

74. Egberts F., Kotthoff E.M., Gerdes S., Egberts J.H., Weichenthal M., Hauschild A.: Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. Eur J Cancer 2012, 48(5): 695 - 702.

75. Egberts F., Momkvist A., Egberts J.H., Kaehler K.C., Hauschild A.: Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients. Anticancer Res 2010, 30(5): 1799 - 1805.

76. Agarwala S.S., Keilholz U., Gilles E., Bedikian A.Y., Wu J., Kay R., Stein C.A., Itri L.M., Suciu S., Eggermont A.M.: LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer 2009, 45(10): 1807 - 1814.

77. Egberts F., Pollex A., Egberts J.H., Kaehler K.C., Weichenthal M., Hauschild A.: Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH. Onkologie 2008, 31(7): 380 - 384.

78. Zhan H., Ma J.Y., Jian Q.C.: Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: A meta-analysis. Clin Chim Acta 2018, 484: 136 - 140.

79. Gao D., Ma X.: Serum lactate dehydrogenase is a predictor of poor survival in malignant melanoma. Panminerva Med 2017, 59(4): 332 - 337.

80. Leiter U., Buettner P.G., Eigentler T.K., Forschner A., Meier F., Garbe C.: Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit? Melanoma Res 2010, 20(3): 240 - 246.

81. Mathews J.D., Forsythe A.V., Brady Z., Butler M.W., Goergen S.K., Byrnes G.B., Giles G.G., Wallace A.B., Anderson P.R., Guiver T.A. et al: Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ 2013, 346: f2360.

82. Rodriguez Rivera A.M., Alabbas H., Ramjaun A., Meguerditchian A.N.: Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. Surg Oncol 2014, 23(1): 11 - 16.

83. Podlipnik S., Carrera C., Sanchez M., Arguis P., Olondo M.L., Vilana R., Rull R., Vidal-Sicart S., Vilalta A., Conill C. et al: Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study. J Am Acad Dermatol 2016, 75(3): 516 - 524.

84. Romano E., Scordo M., Dusza S.W., Coit D.G., Chapman P.B.: Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 2010, 28(18): 3042 - 3047.

85. Xing Y., Bronstein Y., Ross M.I., Askew R.L., Lee J.E., Gershenwald J.E., Royal R., Cormier J.N.: Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 2011, 103(2): 129 - 142.

86. Dinnes J., Ferrante di Ruffano L., Takwoingi Y., Cheung S.T., Nathan P., Matin R.N., Chuchu N., Chan S.A., Durack A., Bayliss S.E. et al: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma. Cochrane Database of Systematic Reviews 2019(7).

87. Lazaga F.J., Oz O.K., Adams-Huet B., Anderson J., Mathews D.: Comparison of whole-body versus limited whole-body 18F-FDG PET/CT scan in malignant cutaneous melanoma. Clin Nucl Med 2013, 38(11): 882 - 884.

88. Ortega-Candil A., Rodriguez-Rey C., Cano-Carrizal R., Cala-Zuluaga E., Gonzalez Larriba J.L., Jimenez-Ballve A., Fuentes-Ferrer M.E., Cabrera-Martin M.N., Perez-Castejon M.J., Garcia Garcia-Esquinas M. et al: Breslow thickness and (18)F-FDG PET-CT result in initial staging of cutaneous melanoma: Can a cut-off point be established? Rev Esp Med Nucl Imagen Mol 2016, 35(2): 96 - 101.

89. Sanchez-Sanchez R., Serrano-Falcon C., Rebollo Aguirre A.C.: Diagnostic imaging in dermatology: utility of PET-CT in cutaneous melanoma. Actas Dermosifiliogr 2015, 106(1): 29 - 34.

90. Jouvet J.C., Thomas L., Thomson V., Yanes M., Journe C., Morelec I., Bracoud L., Durupt F., Giammarile F., Berthezene Y.: Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study. J Eur Acad Dermatol Venereol 2014, 28(2): 176 - 185.

91. Gjorup C.A., Hendel H.W., Pilegaard R.K., Willert C.B., Holmich L.R.: Routine X-ray of the chest is not justified in staging of cutaneous melanoma patients. Dan Med J 2016, 63(12).

92. Aukema T.S., Valdes Olmos R.A., Wouters M.W., Klop W.M., Kroon B.B., Vogel W.V., Nieweg O.E.: Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases. Ann Surg Oncol 2010, 17(10): 2773 - 2778.

93. Aukema T.S., Olmos R.A., Korse C.M., Kroon B.B., Wouters M.W., Vogel W.V., Bonfrer J.M., Nieweg O.E.: Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up. Ann Surg Oncol 2010, 17(6): 1657 - 1661.

94. Tas F., Erturk K.: Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors. Melanoma Res 2017.

95. Suh C.H., Jung S.C., Kim K.W., Pyo J.: The detectability of brain metastases using contrast-enhanced spin-echo or gradient-echo images: a systematic review and meta-analysis. Journal of neuro-oncology 2016, 129(2): 363 - 371.

96. Wang S., Sun S., Liu X., Ge N., Wang G., Guo J., Liu W., Wang S.: Endoscopic diagnosis of primary anorectal melanoma. Oncotarget 2017, 8(30): 50133 - 50140.

97. Pflugfelder A., Weide B., Eigentler T.K., Forschner A., Leiter U., Held L., Meier F., Garbe C.: Incisional biopsy and melanoma prognosis: Facts and controversies. Clin Dermatol 2010, 28(3): 316 - 318.

98. Wheatley K., Wilson J.S., Gaunt P., Marsden J.R.: Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation. Cancer Treat Rev 2016, 42: 73 - 81.

99. Wheatley K., Wilson J.S., Gaunt P., Marsden J.R.: Reply to response to Wheatley et al., "Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation" Cancer Treatment Reviews April 2016; 45: 76. Cancer Treat Rev 2016.

100. Veronesi U., Cascinelli N., Adamus J., Balch C., Bandiera D., Barchuk A., Bufalino R., Craig P., De Marsillac J., Durand J.C. et al: Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988, 318(18): 1159 - 1162.

101. Ringborg U., Andersson R., Eldh J., Glaumann B., Hafstrom L., Jacobsson S., Jonsson P.E., Johansson H., Krysander L., Lagerlof B.: Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer 1996, 77(9): 1809 - 1814.

102. Cohn-Cedermark G., Rutqvist L.E., Andersson R., Breivald M., Ingvar C., Johansson H., Jonsson P.E., Krysander L., Lindholm C., Ringborg U.: Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8 - 2.0 mm. Cancer 2000, 89(7): 1495 - 1501.

103. Balch C.M., Urist M.M., Karakousis C.P., Smith T.J., Temple W.J., Drzewiecki K., Jewell W.R., Bartolucci A.A., Mihm M.C., Jr., Barnhill R. et al: Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993, 218(3): 262 - 267; discussion 267 - 269.

104. Balch C.M., Soong S.J., Smith T., Ross M.I., Urist M.M., Karakousis C.P., Temple W.J., Mihm M.C., Barnhill R.L., Jewell W.R. et al: Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1 - 4 mm melanomas. Ann Surg Oncol 2001, 8(2): 101 - 108.

105. Khayat D., Rixe O., Martin G., Soubrane C., Banzet M., Bazex J.A., Lauret P., Verola O., Auclerc G., Harper P. et al: Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003, 97(8): 1941 - 1946.

106. Thomas J.M., Newton-Bishop J., A'Hern R., Coombes G., Timmons M., Evans J., Cook M., Theaker J., Fallowfield M., O'Neill T. et al: Excision margins in high-risk malignant melanoma. N Engl J Med 2004, 350(8): 757 - 766.

107. Gillgren P., Drzewiecki K.T., Niin M., Gullestad H.P., Hellborg H., Mansson-Brahme E., Ingvar C., Ringborg U.: 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet 2011, 378(9803): 1635 - 1642.

108. Breslow A.: Prognosis in cutaneous melanoma: tumor thickness as a guide to treatment. Pathol Annu 1980, 15 (Pt 1): 1 - 22.

109. Breslow A.: Melanoma thickness and elective node dissection. Arch Dermatol 1978, 114(9): 1399.

110. Breslow A.: Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann Surg 1975, 182(5): 572 - 575.

111. Breslow A.: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970, 172(5): 902 - 908.

112. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Ding S., Byrd D.R., Cascinelli N., Cochran A.J., Coit D.G., Eggermont A.M. et al: Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010, 28(14): 2452 - 2459.

113. Gershenwald J.E., Soong S.J., Balch C.M., American Joint Committee on Cancer Melanoma Staging C: 2010 TNM staging system for cutaneous melanoma... and beyond. Ann Surg Oncol 2010, 17(6): 1475 - 1477.

114. Soong S.J., Ding S., Coit D., Balch C.M., Gershenwald J.E., Thompson J.F., Gimotty P., Force AMT: Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol 2010, 17(8): 2006 - 2014.

115. Balch C.M., Soong S.J., Atkins M.B., Buzaid A.C., Cascinelli N., Coit D.G., Fleming I.D., Gershenwald J.E., Houghton A., Jr., Kirkwood J.M. et al: An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004, 54(3): 131 - 149; quiz 182 - 134.

116. Balch C.M., Wilkerson J.A., Murad T.M., Soong S.J., Ingalls A.L., Maddox W.A.: The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980, 45(12): 3012 - 3017.

117. Balch C.M., Soong S.J., Murad T.M., Ingalls A.L., Maddox W.A.: A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery 1979, 86(2): 343 - 351.

118. Balch C.M., Murad T.M., Soong S.J., Ingalls A.L., Halpern N.B., Maddox W.A.: A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 1978, 188(6): 732 - 742.

119. Dummer R., Hauschild A., Lindenblatt N., Pentheroudakis G., Keilholz U., Committee EG: Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015, 26 Suppl 5: v126 - 132.

120. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W. et al: Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892): 949 - 954.

121. Grob J.J., Amonkar M.M., Karaszewska B., Schachter J., Dummer R., Mackiewicz A., Stroyakovskiy D., Drucis K., Grange F., Chiarion-Sileni V. et al: Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol 2015, 16(13): 1389 - 1398.

122. Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M., Rutkowski P., Blank C.U., Miller W.H., Jr., Kaempgen E. et al: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380(9839): 358 - 365.

123. Long G.V., Weber J.S., Infante J.R., Kim K.B., Daud A., Gonzalez R., Sosman J.A., Hamid O., Schuchter L., Cebon J. et al: Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol 2016.

124. McGettigan S.: Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma. J Adv Pract Oncol 2014, 5(3): 211 - 215.

125. Daud A., Pavlick A.C., Ribas A., Gonzalez R., Lewis K.D., Hamid O., Gajewski T., Puzanov I., Hsu J.J., Koralek D.O. et al: Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib (C) and vemurafenib (V) in BRAF-mutant melanoma. J Clin Oncol 2016, 34 (suppl; abstr 9510).

126. Larkin J., Ascierto P.A., Dreno B., Atkinson V., Liszkay G., Maio M., Mandala M., Demidov L., Stroyakovskiy D., Thomas L. et al: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014, 371(20): 1867 - 1876.

127. Ribas A., Gonzalez R., Pavlick A., Hamid O., Gajewski T.F., Daud A., Flaherty L., Logan T., Chmielowski B., Lewis K. et al: Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol 2014, 15(9): 954 - 965.

128. Dummer R., Ascierto P.A., Gogas H.J., Arance A., Mandala M., Liszkay G., Garbe C., Schadendorf D., Krajsova I., Gutzmer R. et al: Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018.

129. Kim S., Kim H.T., Suh H.S.: Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: a systematic review and meta-analysis. J Dermatolog Treat 2018, 29(3): 314 - 321.

130. Devji T., Levine O., Neupane B., Beyene J., Xie F.: Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. JAMA Oncol 2017, 3(3): 366 - 373.

131. Abu-Abed S., Pennell N., Petrella T., Wright F., Seth A., Hanna W.: KIT gene mutations and patterns of protein expression in mucosal and acral melanoma. J Cutan Med Surg 2012, 16(2): 135 - 142.

132. Abysheva S.N., Iyevleva A.G., Efimova N.V., Mokhina Y.B., Sabirova F.A., Ivantsov A.O., Artemieva A.S., Togo A.V., Moiseyenko V.M., Matsko D.E. et al: KIT mutations in Russian patients with mucosal melanoma. Melanoma Res 2011, 21(6): 555 - 559.

133. Allegra M., Giacchero D., Segalen C., Dumaz N., Butori C., Hofman V., Hofman P., Lacour J.P., Bertolotto C., Bahadoran P. et al: A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib. J Invest Dermatol 2014, 134(5): 1473 - 1476.

134. Bastian B.C., Esteve-Puig R.: Targeting activated KIT signaling for melanoma therapy. J Clin Oncol 2013, 31(26): 3288 - 3290.

135. Becker J.C., Brocker E.B., Schadendorf D., Ugurel S.: Imatinib in melanoma: a selective treatment option based on KIT mutation status? J Clin Oncol 2007, 25(7): e9.

136. Carvajal R.D., Antonescu C.R., Wolchok J.D., Chapman P.B., Roman R.A., Teitcher J., Panageas K.S., Busam K.J., Chmielowski B., Lutzky J. et al: KIT as a therapeutic target in metastatic melanoma. JAMA 2011, 305(22): 2327 - 2334.

137. Hodi F.S., Friedlander P., Corless C.L., Heinrich M.C., Mac Rae S., Kruse A., Jagannathan J., Van den Abbeele A.D., Velazquez E.F., Demetri G.D. et al: Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008, 26(12): 2046 - 2051.

138. Dumaz N., Andre J., Sadoux A., Laugier F., Podgorniak M.P., Mourah S., Lebbe C.: Driver KIT mutations in melanoma cluster in four hotspots. Melanoma Res 2015, 25(1): 88 - 90.

139. Kim J., Lazar A.J., Davies M.A., Homsi J., Papadopoulos N.E., Hwu W.J., Bedikian A.Y., Woodman S.E., Patel S.P., Hwu P. et al: BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol 2012, 39(9): 821 - 825.

140. Lv J., Kong Y., Cai X., Zhou X.: Analysis of KIT and BRAF mutations in Chinese melanoma. Pathology 2016, 48 Suppl 1: S140.

141. Lyu J., Wu Y., Li C., Wang R., Song H., Ren G., Guo W.: Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases. J Oral Pathol Med 2016, 45(4): 295 - 301.

142. McDonnell K., Betz B., Fullen D., Lao C.D.: V559A and N822I double KIT mutant melanoma with predictable response to imatinib? Pigment Cell Melanoma Res 2011, 24(2): 390 - 392.

143. Rapisuwon S., Parks K., Al-Refaie W., Atkins M.B.: Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report. Melanoma Res 2014, 24(5): 509 - 511.

144. Zebary A., Omholt K., Vassilaki I., Hoiom V., Linden D., Viberg L., Kanter-Lewensohn L., Johansson C.H., Hansson J.: KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. J Dermatol Sci 2013, 72(3): 284 - 289.

145. Hodi F.S., Corless C.L., Giobbie-Hurder A., Fletcher J.A., Zhu M., Marino-Enriquez A., Friedlander P., Gonzalez R., Weber J.S., Gajewski T.F. et al: Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013, 31(26): 3182 - 3190.

146. Kim K.B., Eton O., Davis D.W., Frazier M.L., McConkey D.J., Diwan A.H., Papadopoulos N.E., Bedikian A.Y., Camacho L.H., Ross M.I. et al: Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008, 99(5): 734 - 740.

147. Kalinsky K., Lee S., Rubin K.M., Lawrence D.P., Iafrarte A.J., Borger D.R., Margolin K.A., Leitao M.M., Jr., Tarhini A.A., Koon H.B. et al: A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer 2017, 123(14): 2688 - 2697.

148. Guo J., Carvajal R.D., Dummer R., Hauschild A., Daud A., Bastian B.C., Markovic S.N., Queirolo P., Arance A., Berking C. et al: Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Ann Oncol 2017, 28(6): 1380 - 1387.

149. Guo J., Si L., Kong Y., Flaherty K.T., Xu X., Zhu Y., Corless C.L., Li L., Li H., Sheng X. et al: Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011, 29(21): 2904 - 2909.

150. Guo J., Qin S., Liang J., Lin T., Si L., Chen X., Chi Z., Cui C., Du N., Fan Y. et al: Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Chin Clin Oncol 2016, 5(4): 57.

151. Stage I melanoma of the skin: the problem of resection margins. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma. Eur J Cancer 1980, 16(8): 1079 - 1085.

152. Shelley W., Kersey P., Quirt I., Pater J.: Survey of surgical management of malignant melanoma in Canada: optimal margins of excision and lymph-node dissection. Can J Surg 1984, 27(2): 190 - 192.

153. Demidov L.V., Martynova E.V.: [Retrospective evaluation of the safe reduction of surgical margins of resected stage-IIA cutaneous melanoma of the trunk and extremities]. Vopr Onkol 2002, 48(1): 68 - 73.

154. Lens M.B., Newton-Bishop J.A., Dawes M.: Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2004, 100(2): 433 - 434; author reply 434.

155. Thompson J.F., Scolyer R.A., Uren R.F.: Surgical management of primary cutaneous melanoma: excision margins and the role of sentinel lymph node examination. Surg Oncol Clin N Am 2006, 15(2): 301 - 318.

156. Mocellin S., Pasquali S., Nitti D.: The impact of surgery on survival of patients with cutaneous melanoma: revisiting the role of primary tumor excision margins. Ann Surg 2011, 253(2): 238 - 243.

157. Duffy K.L., Truong A., Bowen G.M., Andtbacka R.H., Hyngstrom J., Bowles T., Grossmann K., Khong H., Hyde M., Florell S.R. et al: Adequacy of 5-mm surgical excision margins for non-lentiginous melanoma in situ. J Am Acad Dermatol 2014, 71(4): 835 - 838.

158. Koskivuo I., Giordano S., Verajankorva E., Vihinen P.: One-cm Versus 2-cm Excision Margins for Patients With Intermediate Thickness Melanoma: A Matched-Pair Analysis. Dermatol Surg 2015, 41(10): 1130 - 1136.

159. Faries M.B., Mozzillo N., Kashani-Sabet M., Thompson J.F., Kelley M.C., DeConti R.C., Lee J.E., Huth J.F., Wagner J., Dalgleish A. et al: Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. Ann Surg Oncol 2017, 24(13): 3991 - 4000.

160. Morton D.L., Thompson J.F., Cochran A.J., Mozzillo N., Nieweg O.E., Roses D.F., Hoekstra H.J., Karakousis C.P., Puleo C.A., Coventry B.J. et al: Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014, 370(7): 599 - 609.

161. Felton S., Taylor R.S., Srivastava D.: Excision Margins for Melanoma In Situ on the Head and Neck. Dermatol Surg 2016, 42(3): 327 - 334.

162. Rawlani R., Rawlani V., Qureshi H.A., Kim J.Y., Wayne J.D.: Reducing margins of wide local excision in head and neck melanoma for function and cosmesis: 5-year local recurrence-free survival. J Surg Oncol 2015, 111(7): 795 - 799.

163. Moehrle M., Metzger S., Schippert W., Garbe C., Rassner G., Breuninger H.: "Functional" surgery in subungual melanoma. Dermatol Surg 2003, 29(4): 366 - 374.

164. Pockaj B.A., Jaroszewski D.E., DiCaudo D.J., Hentz J.G., Buchel E.W., Gray R.J., Markovic S.N., Bite U.: Changing surgical therapy for melanoma of the external ear. Ann Surg Oncol 2003, 10(6): 689 - 696.

165. Farshad A., Burg G., Panizzon R., Dummer R.: A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002, 146(6): 1042 - 1046.

166. Harwood A.R.: Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. Int J Radiat Oncol Biol Phys 1983, 9(7): 1019 - 1021.

167. Hedblad M.A., Mallbris L.: Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma. J Am Acad Dermatol 2012, 67(1): 60 - 68.

168. Chen J.Y., Hruby G., Scolyer R.A., Murali R., Hong A., Fitzgerald P., Pham T.T., Quinn M.J., Thompson J.F.: Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer 2008, 113(10): 2770 - 2778.

169. Christie D.R., Tiver K.V.: Radiotherapy for melanotic freckles. Austral Radiol 1996, 40: 331 - 333.

170. Testori A., Soteldo J., Powell B., Sales F., Borgognoni L., Rutkowski P., Lejeune F., van Leeuwen P., Eggermont A.: Surgical management of melanoma: an EORTC Melanoma Group survey. Ecancermedicalscience 2013, 7: 294.

171. Lens M.B., Dawes M., Goodacre T., Newton-Bishop J.A.: Elective lymph node dissection in patients with melanoma: systematic review and meta-analysis of randomized controlled trials. Arch Surg 2002, 137(4): 458 - 461.

172. Yonick D.V., Ballo R.M., Kahn E., Dahiya M., Yao K., Godellas C., Shoup M., Aranha G.V.: Predictors of positive sentinel lymph node in thin melanoma. Am J Surg 2011, 201(3): 324 - 327; discussion 327 - 328.

173. Cascinelli N., Belli F., Santinami M., Fait V., Testori A., Ruka W., Cavaliere R., Mozzillo N., Rossi C.R., MacKie R.M. et al: Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000, 7(6): 469 - 474.

174. Stoffels I., Dissemond J., Poppel T., Schadendorf D. Klode J.: Intraoperative Fluorescence Imaging for Sentinel Lymph Node Detection: Prospective Clinical Trial to Compare the Usefulness of Indocyanine Green vs Technetium Tc 99m for Identification of Sentinel Lymph Nodes. JAMA Surg 2015, 150(7): 617 - 623.

175. de Bree E., de Bree R.: Implications of the MSLT-1 for sentinel lymph node biopsy in cutaneous head and neck melanoma. Oral Oncol 2015, 51(7): 629 - 633.

176. van Akkooi A.C., Eggermont A.M.: Melanoma: MSLT-1--SNB is a biomarker, not a therapeutic intervention. Nat Rev Clin Oncol 2014, 11(5): 248 - 249.

177. Ross MI, Gershenwald JE: How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? Ann Surg Oncol 2008, 15(3): 670 - 673.

178. Morton D.L.: Intraoperative lymphatic mapping and sentinel lymphadenectomy: community standard care or clinical investigation? Cancer J Sci Am 1997, 3(6): 328 - 330.

179. Morton D.L., Cochran A.J., Thompson J.F., Elashoff R., Essner R., Glass E.C., Mozzillo N., Nieweg O.E., Roses D.F., Hoekstra H.J. et al: Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005, 242(3): 302 - 311; discussion 311 - 303.

180. Faries M.B., Thompson J.F., Cochran A.J., Andtbacka R.H., Mozzillo N., Zager J.S., Jahkola T., Bowles T.L., Testori A., Beitsch P.D. et al: Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 2017, 376(23): 2211 - 2222.

181. Bostick P.J., Morton D.L., Turner R.R., Huynh K.T., Wang H.J., Elashoff R., Essner R., Hoon D.S.: Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999, 17(10): 3238 - 3244.

182. van der Velde-Zimmermann D., Schipper M.E., de Weger R.A., Hennipman A., Borel Rinkes I.H.: Sentinel node biopsies in melanoma patients: a protocol for accurate, efficient, and cost-effective analysis by preselection for immunohistochemistry on the basis of Tyr-PCR. Ann Surg Oncol 2000, 7(1): 51 - 54.

183. Eggermont A.M., Keilholz U., Testori A., Cook M., Lienard D., Ruiter D.J.: The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer. Ann Surg Oncol 2001, 8(9 Suppl): 38S - 40S.

184. Spanknebel K., Coit D.G., Bieligk S.C., Gonen M., Rosai J., Klimstra D.S.: Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol 2005, 29(3): 305 - 317.

185. Laga A.C., Zhan Q., Weishaupt C., Ma J., Frank M.H., Murphy G.F.: SOX2 and nestin expression in human melanoma: an immunohistochemical and experimental study. Exp Dermatol 2011, 20(4): 339 - 345.

186. Lee J.J., Granter S.R., Laga A.C., Saavedra A.P., Zhan Q., Guo W., Xu S., Murphy G.F., Lian C.G.: 5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies. Mod Pathol 2015, 28(2): 218 - 229.

187. Chen P.L., Chen W.S., Li J., Lind A.C., Lu D.: Diagnostic utility of neural stem and progenitor cell markers nestin and SOX2 in distinguishing nodal melanocytic nevi from metastatic melanomas. Mod Pathol 2013, 26(1): 44 - 53.

188. Satzger I., Volker B., Meier A., Schenck F., Kapp A., Gutzmer R.: Prognostic significance of isolated HMB45 or Melan A positive cells in Melanoma sentinel lymph nodes. Am J Surg Pathol 2007, 31(8): 1175 - 1180.

189. Scolyer R.A., Judge M.J., Evans A., Frishberg D.P., Prieto V.G., Thompson J.F., Trotter M.J., Walsh M.Y., Walsh N.M., Ellis D.W. et al: Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR). Am J Surg Pathol 2013, 37(12): 1797 - 1814.

190. Shidham V.B., Qi D., Rao R.N., Acker S.M., Chang C.C., Kampalath B., Dawson G., Machhi J.K., Komorowski R.A.: Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with "MCW melanoma cocktail"--a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase. BMC Cancer 2003, 3: 15.

191. Murray C.A., Leong W.L., McCready D.R., Ghazarian D.M.: Histopathological patterns of melanoma metastases in sentinel lymph nodes. J Clin Pathol 2004, 57(1): 64 - 67.

192. Vitoux D., Mourah S., Kerob D., Verola O., Basset-Seguin N., Baccard M., Schartz N., Ollivaud L., Archimbaud A., Servant J.M. et al: Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases. Arch Dermatol 2009, 145(10): 1105 - 1113.

193. Rimoldi D., Lemoine R., Kurt A.M., Salvi S., Berset M., Matter M., Roche B., Cerottini J.P., Guggisberg D., Krischer J. et al: Detection of micrometastases in sentinel lymph nodes from melanoma patients: direct comparison of multimarker molecular and immunopathological methods. Melanoma Res 2003, 13(5): 511 - 520.

194. Baisden B.L., Askin F.B., Lange J.R., Westra W.H.: HMB-45 immunohistochemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastases in patients with melanoma. Am J Surg Pathol 2000, 24(8): 1140 - 1146.

195. Lukowsky A., Bellmann B., Ringk A., Winter H., Audring H., Fenske S., Sterry W.: Detection of melanoma micrometastases in the sentinel lymph node and in nonsentinel nodes by tyrosinase polymerase chain reaction. J Invest Dermatol 1999, 113(4): 554 - 559.

196. Voit C.A., Oude Ophuis C.M., Ulrich J., van Akkooi A.C., Eggermont A.M.: Ultrasound of the sentinel node in melanoma patients: echo-free island is a discriminatory morphologic feature for node positivity. Melanoma Res 2016, 26(3): 267 - 271.

197. Voit C.A., Gooskens S.L., Siegel P., Schaefer G., Schoengen A., Rowert J., van Akkooi A.C., Eggermont A.M.: Ultrasound-guided fine needle aspiration cytology as an addendum to sentinel lymph node biopsy can perfect the staging strategy in melanoma patients. Eur J Cancer 2014, 50(13): 2280 - 2288.

198. Voit C.A., van Akkooi A.C., Schafer-Hesterberg G., Schoengen A., Schmitz P.I., Sterry W., Eggermont A.M.: Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma? J Clin Oncol 2009, 27(30): 4994 - 5000.

199. Voit C., Schoengen A., Schwurzer-Voit M., Weber L., Ulrich J., Sterry W., Proebstle T.M.: The role of ultrasound in detection and management of regional disease in melanoma patients. Semin Oncol 2002, 29(4): 353 - 360.

200. АЛЛАХВЕРДЯН Г.С., ЧЕКАЛОВА М.А., КОКОСАДЗЕ Н.В.: ВОЗМОЖНОСТИ УЛЬТРАЗВУКОВОГО ИССЛЕДОВАНИЯ В РАННЕЙ ДИАГНОСТИКЕ МЕТАСТАЗОВ МЕЛАНОМЫ КОЖИ В РЕГИОНАРНЫХ ЛИМФАТИЧЕСКИХ УЗЛАХ. ДИАГНОСТИЧЕСКАЯ И ИНТЕРВЕНЦИОННАЯ РАДИОЛОГИЯ 2013, 7(4-4): 9 - 14.

201. Torabi S.J., Benchetrit L., Spock T., Cheraghlou S., Judson B.L.: Clinically node-negative head and neck mucosal melanoma: An analysis of current treatment guidelines & outcomes. Oral Oncol 2019, 92: 67 - 76.

202. Ramesh M., Nanda S., Misra B.: Mucosal melanoma of the head-and-neck region: A single institutional clinical experience. South Asian J Cancer 2019, 8(1): 26.

203. Prinzen T., Klein M., Hallermann C., Wermker K.: Primary head and neck mucosal melanoma: Predictors of survival and a case series on sentinel node biopsy. J Craniomaxillofac Surg 2019.

204. Moya-Plana A., Mangin D., Dercle L., Taouachi R., Casiraghi O., Ammari S., Nguyen F., Temam S., Robert C., Gorphe P.: Risk-based stratification in head and neck mucosal melanoma. Oral Oncol 2019, 97: 44 - 49.

205. Yao J.J., Zhang F., Zhang G.S., Deng X.W., Zhang W.J., Lawrence W.R., Zou L., Zhang X.S., Lu L.X.: Efficacy and safety of primary surgery with postoperative radiotherapy in head and neck mucosal melanoma: a single-arm Phase II study. Cancer Manag Res 2018, 10: 6985 - 6996.

206. Comoglu S., Polat B., Celik M., Sahin B., Enver N., Keles M.N., Sari S.O.: Prognostic factors in head and neck mucosal malignant melanoma. Auris Nasus Larynx 2018, 45(1): 135 - 142.

207. Игнатова А.В., Мудунов А.М., Подвязников С.О.: Особенности клинического течения меланомы слизистых оболочек головы и шеи. Обзор литературы. Опухоли головы и шеи 2015, 5(4): 48 - 52.

208. Amit M., Tam S., Abdelmeguid A.S., Roberts D.B., Raza S.M., Su S.Y., Kupferman M.E., DeMonte F., Hanna E.Y.: Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma. Cancer 2018, 124(3): 514 - 520.

209. Clark R.R., Shoaib T.: Sentinel lymph node biopsy: a new perspective in head and neck mucosal melanoma? Melanoma Res 2007, 17(1): 59.

210. Francisco A.L., Furlan M.V., Peresi P.M., Nishimoto I.N., Lourenco S.V., Pinto C.A., Kowalski L.P., Ikeda M.K.: Head and neck mucosal melanoma: clinicopathological analysis of 51 cases treated in a single cancer centre and review of the literature. Int J Oral Maxillofac Surg 2016, 45(2): 135 - 140.

211. Green B., Elhamshary A., Gomez R., Rahimi S., Brennan P.A.: An update on the current management of head and neck mucosal melanoma. J Oral Pathol Med 2017, 46(7): 475 - 479.

212. Loree T.R., Mullins A.P., Spellman J., North J.H., Jr., Hicks W.L., Jr.: Head and neck mucosal melanoma: a 32-year review. Ear Nose Throat J 1999, 78(5): 372 - 375.

213. Lourenco S.V., Fernandes J.D., Hsieh R., Coutinho-Camillo C.M., Bologna S., Sangueza M., Nico M.M.: Head and neck mucosal melanoma: a review. Am J Dermatopathol 2014, 36(7): 578 - 587.

214. Luna-Ortiz K., Villavicencio-Valencia V., Martinez Said H.: Comparative study of head and neck mucosal melanoma in 66 patients vs 226 patients with cutaneous melanoma: A survival analysis. Clin Otolaryngol 2018, 43(2): 691 - 696.

215. Meleti M., Leemans C.R., de Bree R., Vescovi P., Sesenna E., van der Waal I.: Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy. Head Neck 2008, 30(12): 1543 - 1551.

216. Diller M.L., Martin B.M., Delman K.A.: Lymph node dissection for stage III melanoma. Surg Oncol Clin N Am 2015, 24(2): 261 - 277.

217. Mozzillo N., Caraco C., Marone U., Di Monta G., Crispo A., Botti G., Montella M., Ascierto P.A.: Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors. World J Surg Oncol 2013, 11: 36.

218. Galliot-Repkat C., Cailliod R., Trost O., Danino A., Collet E., Lambert D., Vabres P., Dalac S.: The prognostic impact of the extent of lymph node dissection in patients with stage III melanoma. Eur J Surg Oncol 2006, 32(7): 790 - 794.

219. Hughes T.M., Thomas J.M.: Combined inguinal and pelvic lymph node dissection for stage III melanoma. Br J Surg 1999, 86(12): 1493 - 1498.

220. Shen P., Conforti A.M., Essner R., Cochran A.J., Turner R.R., Morton D.L.: Is the node of Cloquet the sentinel node for the iliac/obturator node group? Cancer J 2000, 6(2): 93 - 97.

221. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., Buzaid A.C., Cochran A.J., Coit D.G., Ding S. et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27(36): 6199 - 6206.

222. Kirkwood J.M., Manola J., Ibrahim J., Sondak V., Ernstoff M.S., Rao U.: A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004, 10(5): 1670 - 1677.

223. Petrella T.: Systemic Adjuvant Therapy for Patients at High Risk for Recurrent Melanoma: Updated Guideline Recommendations 2009. In: Evidence-based Series #8-1 Version 32009: Section 1. 2009.

224. Kirkwood J.M., Ibrahim J.G., Sondak V.K., Richards J., Flaherty L.E., Ernstoff M.S., Smith T.J., Rao U., Steele M., Blum R.H.: High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000, 18(12): 2444 - 2458.

225. Kirkwood J.M., Ibrahim J.G., Sosman J.A., Sondak V.K., Agarwala S.S., Ernstoff M.S., Rao U.: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB - III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001, 19(9): 2370 - 2380.

226. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., Blum R.H.: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14(1): 7 - 17.

227. Wheatley K., Ives N., Eggermont A., Kirkwood J., Cascinelli N., Markovic S.N., Hancock B., Lee S., Suciu S., on behalf of International Malignant Melanoma Collaborative Group: Interferon-(alpha) as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. ASCO Meeting Abstracts 2007, 25(18_suppl): 8526.

228. Eggermont A.M.M., Blank C.U., Mandala M., Long G.V., Atkinson V., Dalle S., Haydon A., Lichinitser M., Khattak A., Carlino M.S. et al: Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med 2018, 378(19): 1789 - 1801.

229. Long G.V., Hauschild A., Santinami M., Atkinson V., Mandala M., Chiarion-Sileni V., Larkin J., Nyakas M., Dutriaux C., Haydon A. et al: Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med 2017, 377(19): 1813 - 1823.

230. Weber J., Mandala M., Del Vecchio M., Gogas H.J., Arance A.M., Cowey C.L., Dalle S., Schenker M., Chiarion-Sileni V., Marquez-Rodas I. et al: Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 2017, 377(19): 1824 - 1835.

231. Burmeister B.H., Henderson M.A., Ainslie J., Fisher R., Di Iulio J., Smithers B.M., Hong A., Shannon K., Scolyer R.A., Carruthers S. et al: Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012, 13(6): 589 - 597.

232. Henderson M.A., Burmeister B.H., Ainslie J., Fisher R., Di Iulio J., Smithers B.M., Hong A., Shannon K., Scolyer R.A., Carruthers S. et al: Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol 2015, 16(9): 1049 - 1060.

233. Beadle B.M., Guadagnolo B.A., Ballo M.T., Lee J.E., Gershenwald J.E., Cormier J.N., Mansfield P.F., Ross M.I., Zagars G.K.: Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2009, 73(5): 1376 - 1382.

234. Bibault J.E., Dewas S., Mirabel X., Mortier L., Penel N., Vanseymortier L., Lartigau E.: Adjuvant radiation therapy in metastatic lymph nodes from melanoma. Radiat Oncol 2011, 6: 12.

235. Adams G., Foote M., Brown S., Burmeister B.: Adjuvant external beam radiotherapy after therapeutic groin lymphadenectomy for patients with melanoma: a dosimetric comparison of three-dimensional conformal and intensity-modulated radiotherapy techniques. Melanoma Res 2017, 27(1): 50 - 56.

236. Mattes M.D., Zhou Y., Berry S.L., Barker C.A.: Dosimetric comparison of axilla and groin radiotherapy techniques for high-risk and locally advanced skin cancer. Radiat Oncol J 2016, 34(2): 145 - 155.

237. Sause W.T., Cooper J.S., Rush S., Ago C.T., Cosmatos D., Coughlin C.T., JanJan N., Lipsett J.: Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991, 20(3): 429 - 432.

238. Sobin L.H., Gospodarowicz M.K., Wittekind C. (eds.): The TNM classification of malignant tumours 8th edition, 8th edn: Wiley-Blackwell; 2009.

239. Eggermont A.M., Suciu S., Santinami M., Testori A., Kruit W.H., Marsden J., Punt C.J., Sales F., Gore M., Mackie R. et al: Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008, 372(9633): 117 - 126.

240. Mocellin S., Pasquali S., Rossi C.R., Nitti D.: Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010, 102(7): 493 - 501.

241. Ives N.J., Suciu S., Eggermont A.M.M., Kirkwood J., Lorigan P., Markovic S.N., Garbe C., Wheatley K., International Melanoma Meta-Analysis Collaborative G.: Adjuvant interferon-alpha for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer 2017, 82: 171 - 183.

242. Pehamberger H., Soyer H.P., Steiner A., Kofler R., Binder M., Mischer P., Pachinger W., Aubock J. Fritsch P., Kerl H. et al: Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998, 16(4): 1425 - 1429.

243. Lala M., Li T.R., de Alwis D.P., Sinha V., Mayawala K., Yamamoto N., Siu L.L., Chartash E., Aboshady H., Jain L.: A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur J Cancer 2020, 131: 68 - 75.

244. Zhao X., Suryawanshi S., Hruska M., Feng Y., Wang X., Shen J., Vezina H.E., McHenry M.B., Waxman I.M., Achanta A. et al: Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol 2017, 28(8): 2002 - 2008.

245. Long G.V., Tykodi S.S., Schneider J.G., Garbe C., Gravis G., Rashford M, Agrawal S., Grigoryeva E., Bello A., Roy A. et al: Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol 2018, 29(11): 2208 - 2213.

246. Barth A., Morton D.L.: The role of adjuvant therapy in melanoma management. Cancer 1995, 75(2 Suppl): 726 - 734.

247. Chiarion-Sileni V., Del Bianco P., Romanini A., Guida M., Paccagnella A., Dalla Palma M., Naglieri E., Ridolfi R., Silvestri B., Michiara M. et al: Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]. BMC Cancer 2006, 6: 44.

248. Gogas H., Bafaloukos D., Ioannovich J., Skarlos D., Polyzos A., Fountzilas G., Kalofonos H.P, Aravantinos G., Tsoutsos D., Panagiotou P. et al: Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study. Anticancer Res 2004, 24(3b): 1947 - 1952.

249. Hauschild A., Gogas H, Tarhini A., Middleton MR, Testori A., Dreno B, Kirkwood JM: Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008, 112(5): 982 - 994.

250. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., Langer C., Murphy B., Cumberlin R., Coleman C.N. et al: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13(3): 176 - 181.

251. Mohr P., Hauschild A., Enk A., Trefzer U., Rass K., Grabbe S., Brockmeyer N.H., Koller J., Gogas H., Weichenthal M.: Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: An interim analysis of a randomized phase III study (NCT00226408). J Clin Oncol 2008, 26(suppl.).

252. Veronesi U., Adamus J., Aubert C., Bajetta E., Beretta G., Bonadonna G., Bufalino R., Cascinelli N., Cocconi G., Durand J. et al: A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982, 307(15): 913 - 916.

253. Balch C.M., Murray D., Presant C., Bartolucci A.A.: Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma. Surgery 1984, 95(4): 454 - 459.

254. Tranum B.L., Dixon D., Quagliana J., Neidhart J., Balcerzak S.P., Costanzi J.H., Fabian C.J., Neilan B., Maloney T., O'Bryan R.M. et al: Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study. Cancer Treat Rep 1987, 71(6): 643 - 644.

255. Saba H.I., Cruse C.W., Wells K.E., Klein C.J., Reintgen D.S.: Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Ann Plast Surg 1992, 28(1): 60 - 64.

256. Stables G.I., Doherty V.R., MacKie R.M.: Nine years' experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma. Br J Dermatol 1992, 127(5): 505 - 508.

257. Karakousis C., Blumenson L.: Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma. Eur J Cancer 1993, 29A (13): 1831 - 1835.

258. Pectasides D., Alevizakos N., Bafaloukos D., Tzonou A., Asimakopoulos G., Varthalitis I., Dimitriadis M., Athanassiou A.: Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma. Am J Clin Oncol 1994, 17(1): 55 - 59.

259. Garbe C., Radny P., Linse R., Dummer R., Gutzmer R., Ulrich J., Stadler R., Weichenthal M., Eigentler T., Ellwanger U. et al: Adjuvant low-dose interferon (alpha)2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 2008, 19(6): 1195 - 1201.

260. Kleeberg U.R., Suciu S., Brocker E.B., Ruiter D.J., Chartier C., Lienard D., Marsden J., Schadendorf D., Eggermont A.M.: Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness > 3 mm) or regional lymph node metastasis. Eur J Cancer 2004, 40(3): 390 - 402.

261. Eigentler T.K., Gutzmer R., Hauschild A., Heinzerling L., Schadendorf D., Nashan D., Holzle E., Kiecker F., Becker J., Sunderkotter C. et al: Adjuvant treatment with pegylated interferon alpha-2a versus low-dose interferon alpha-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. Ann Oncol 2016, 27(8): 1625 - 1632.

262. Hauschild A., Weichenthal M., Rass K., Linse R., Ulrich J., Stadler R., Volkenandt M., Grabbe S., Proske U., Schadendorf D. et al: Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. J Clin Oncol 2009, 27(21): 3496 - 3502.

263. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., Carbone P.P.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5(6): 649 - 655.

264. Simmons C., McMillan D.C., Tuck S., Graham C., McKeown A., Bennett M., O'Neill C., Wilcock A., Usborne C., Fearon K.C. et al: "How Long Have I Got?" - A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer. Oncologist 2019.

265. Tse A., Verkhivker G.M.: Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways. PLoS One 2016, 11(11): e0166583.

266. Zhang C., Spevak W., Zhang Y., Burton E.A., Ma Y., Habets G., Zhang J., Lin J., Ewing T., Matusow B. et al: RAF inhibitors that evade paradoxical MAPK pathway activation. Nature 2015, 526(7574): 583 - 586.

267. Long G.V., Stroyakovskiy D., Gogas H., Levchenko E., de Braud F., Larkin J., Garbe C., Jouary T, Hauschild A., Grob J.J. et al: Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015, 386(9992): 444 - 451.

268. Weber J.S., D'Angelo S.P., Minor D., Hodi F.S., Gutzmer R., Neyns B., Hoeller C., Khushalani N.I., Miller W.H., Jr., Lao C.D. et al: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015, 16(4): 375 - 384.

269. Ribas A., Puzanov I., Dummer R., Schadendorf D., Hamid O., Robert C., Hodi F.S., Schachter J., Pavlick A.C., Lewis K.D. et al: Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015, 16(8): 908 - 918.

270. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D., Schadendorf D., Dummer R., Smylie M., Rutkowski P. et al: Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015, 373(1): 23 - 34.

271. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., Weber J.S., Joshua A.M., Hwu W.J., Gangadhar T.C. et al: Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384(9948): 1109 - 1117.

272. Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., Daud A., Carlino M.S., McNeil C., Lotem M. et al: Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015, 372(26): 2521 - 2532.

273. Ribas A., Hamid O, Daud A., Hodi F.S., Wolchok J.D., Kefford R., Joshua A.M., Patnaik A., Hwu W.J., Weber J.S. et al: Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA 2016, 315(15): 1600 - 1609.

274. Larkin J., Chiarion-Sileni V., Gonzalez R., Rutkowski P., Grob J., Cowey C.L., Lao C.D., Schadendorf D., Ferrucci P.F., Smylie M. et al: Overall Survival Results From a Phase III Trial of Nivolumab Combined With Ipilimumab in Treatment- Patients With Advanced Melanoma (CheckMate 067). In: AACR Annual Meeting: April 1 - 5 2017; Walter E. Washington Convention Center, Washington, D.C., USA; 2017.

275. Liu M., Yang X., Liu J., Zhao B., Cai W., Li Y., Hu D.: Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials. Oncotarget 2017, 8(19): 32258 - 32269.

276. Hao C., Tian J., Liu H., Li F., Niu H., Zhu B.: Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2017, 96(26): e7325.

277. Sosman J.A, Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., McArthur G.A., Hutson T.E., Moschos S.J, Flaherty K.T. et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366(8): 707 - 714.

278. McArthur G.A., Chapman P.B., Robert C., Larkin J., Haanen J.B., Dummer R., Ribas A., Hogg D., Hamid O., Ascierto P.A. et al: Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014, 15(3): 323 - 332.

279. Long G.V., Trefzer U., Davies M.A., Kefford R.F., Ascierto P.A., Chapman P.B., Puzanov I., Hauschild A., Robert C., Algazi A. et al: Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13(11): 1087 - 1095.

280. Sanlorenzo M., Choudhry A., Vujic I., Posch C., Chong K., Johnston K., Meier M., Osella-Abate S., Quaglino P., Daud A. et al: Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol 2014, 71(6): 1102 - 1109 e1101.

281. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M. et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2): 228 - 247.

282. Miller A.B., Hoogstraten B., Staquet M., Winkler A.: Reporting results of cancer treatment. Cancer 1981, 47(1): 207 - 214.

283. Larkin J., Lao C.D., Urba W.J., McDermott D.F., Horak C., Jiang J., Wolchok J.D.: Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. JAMA Oncol 2015, 1(4): 433 - 440.

284. Kreft S., Gesierich A., Eigentler T., Franklin C., Valpione S., Ugurel S., Utikal J., Haferkamp S., Blank C., Larkin J. et al: Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. Eur J Cancer 2019, 116: 207 - 215.

285. Modification of the Dosage Regimen for Nivolumab [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm520871.htm]

286. Fogt S., Shustova M., Demidov L.V., Moiseyenko V., Tjulandin S., Semiglazova T., Protsenko S., Odintsova S., Zukov R., Lazarev S. et al: Phase II trial (BCD-100-2/MIRACULUM) of the novel PD-1 inhibitor (BCD-100) in patients with advanced melanoma. Journal of Clinical Oncology 2019, 37(15_suppl): 9549 - 9549.

287. Tjulandin S., Fedyanin M., Demidov L., Moiseyenko V., Protsenko S., Odintsova S., Semiglazova T.Y., Zukov R., Lazarev S., Andreev A. et al: FINAL RESULTS OF PHASE II TRIAL (MIRACULUM) OF THE NOVEL PD-1 INHIBITOR PROLGOLIMAB IN PATIENTS WITH ADVANCED MELANOMA. Annals of Oncology 2019, 30: xi33 - xi47.

288. Long G.V., Atkinson V., Lo S., Sandhu S., Guminski A.D., Brown M.P., Wilmott J.S., Edwards J., Gonzalez M., Scolyer R.A. et al: Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 2018, 19(5): 672 - 681.

289. Lebbe C., Meyer N., Mortier L., Marquez-Rodas I., Robert C., Rutkowski P., Menzies A.M., Eigentler T., Ascierto P.A., Smylie M. et al: Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. J Clin Oncol 2019, 37(11): 867 - 875.

290. Yang H., Higgins B., Kolinsky K., Packman K., Go Z., Iyer R., Kolis S., Zhao S., Lee R., Grippo J.F. et al: RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010, 70(13): 5518 - 5527.

291. Johnson D.B., Menzies A.M., Zimmer L., Eroglu Z., Ye F., Zhao S., Rizos H., Sucker A., Scolyer R.A., Gutzmer R. et al: Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer 2015, 51(18): 2792 - 2799.

292. Zimmer L., Apuri S., Eroglu Z., Kottschade L.A., Forschner A., Gutzmer R., Schlaak M., Heinzerling L., Krackhardt A.M., Loquai C. et al: Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer 2017, 75: 47 - 55.

293. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C. et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8): 711 - 723.

294. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J.F., Testori A., Grob J.J. et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364(26): 2517 - 2526.

295. Самойленко И.В., Харкевич Г.Ю., Демидов Л.В.: ПРИМЕНЕНИЕ БЛОКАТОРА РЕЦЕПТОРОВ CTLA4 В ЛЕЧЕНИИ БОЛЬНЫХ МЕТАСТАТИЧЕСКОЙ МЕЛАНОМОЙ. РОССИЙСКИЙ МЕДИЦИНСКИЙ ЖУРНАЛ 2015, 21(1): 4 - 9.

296. Li J., Gu J.: Efficacy and safety of ipilimumab for treating advanced melanoma: A systematic review and meta-analysis. J Clin Pharm Ther 2019, 44(3): 420 - 429.

297. Zhang S., Liang F., Li W., Wang Q.: Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis. Eur J Cancer 2017, 83: 71 - 79.

298. Yi J.H., Yi S.Y., Lee H.R., Lee S.I., Lim D.H., Kim J.H., Park K.W., Lee J.: Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia. Melanoma Res 2011, 21(3): 223 - 227.

299. Serrone L., Zeuli M., Sega F.M., Cognetti F.: Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000, 19(1): 21 - 34.

300. Hill G.J., 2nd, Krementz E.T., Hill H.Z.: Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 1984, 53(6): 1299 - 1305.

301. Middleton M.R., Grob J.J., Aaronson N., Fierlbeck G., Tilgen W., Seiter S., Gore M., Aamdal S., Cebon J., Coates A. et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000, 18(1): 158 - 166.

302. МАНЗЮК Л., БОРОДКИНА А., АРТАМОНОВА Е., НАДЕЖДИНА Т., ТОКАРЕВА З., ХАЛЯСТОВ И.: Опыт применения лекарственных комбинаций на основе аранозы при лечении диссеминированной меланомы кожи. Вестник РОНЦ им Н.Н. Блохина РАМН 2000, 11(2): 4.

303. Hauschild A., Agarwala S.S., Trefzer U., Hogg D., Robert C., Hersey P., Eggermont A., Grabbe S, Gonzalez R., Gille J. et al: Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009, 27(17): 2823 - 2830.

304. Samoylenko I., Kharkevich G., Petenko N.N., Orlova K., Sinelnikov I., Utyashev I., Vikhrova A., Markina I., Demidov L.: Paclitaxel and carboplatin chemotherapy in patients with metastatic melanoma refractory to BRAF/MEK inhibitors. J Clin Oncol 2016, 34: No 15_suppl (May 20 Supplement), 2016: 9552.

305. Ives N.J., Stowe R.L., Lorigan P., Wheatley K.: Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007, 25(34): 5426 - 5434.

306. Atkins M.B., Hsu J., Lee S., Cohen G.I., Flaherty L.E., Sosman J.A., Sondak V.K., Kirkwood J.M., Eastern Cooperative Oncology G.: Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008, 26(35): 5748 - 5754.

307. Carbone P.P., Costello W.: Eastern Cooperative Oncology Group studies with DTIC (NSC-45388). Cancer Treat Rep 1976, 60(2): 193 - 198.

308. Nashan D., Muller M.L., Grabbe S., Wustlich S., Enk A.: Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine. J Eur Acad Dermatol Venereol 2007, 21(10): 1305 - 1318.

309. Larkin J.M., Hughes S.A., Beirne D.A., Patel P.M., Gibbens I.M., Bate S.C., Thomas K., Eisen T.G., Gore M.E.: A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer 2007, 96(1): 44 - 48.

310. Ahmann D.L., Hahn R.G., Bisel H.F.: A Comparative Study of 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) and Imidazole Carboxamide (NSC 45388) with Vincristine (NSC 67574) in the Palliation of Disseminated Malignant Melanoma. Cancer Research 1972, 32(11): 2432 - 2434.

311. Hill G.J., 2nd, Ruess R., Berris R., Philpott G.W., Parkin P.: Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU). Ann Surg 1974, 180(2): 167 - 174.

312. Eton O., Legha S.S., Bedikian A.Y., Lee J.J., Buzaid A.C., Hodges C., Ring S.E., Papadopoulos N.E., Plager C., East M.J. et al: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002, 20(8): 2045 - 2052.

313. Larkin J., Minor D., D'Angelo S., Neyns B., Smylie M., Miller W.H., Jr., Gutzmer R., Linette G., Chmielowski B., Lao C.D. et al: Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol 2017: JCO2016718023.

314. Gurney H.: How to calculate the dose of chemotherapy. Br J Cancer 2002, 86(8): 1297 - 1302.

315. de Jongh F.E., Verweij J., Loos W.J., de Wit R., de Jonge M.J., Planting A.S., Nooter K., Stoter G., Sparreboom A.: Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001, 19(17): 3733 - 3739.

316. Da Silva I.P., Ahmed T., Lo S., Reijers I.L.M., Weppler A., Warner A.B., Patrinely J.R., Serra-Bellver P., Lebbe C, Mangana J et al: Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. J Clin Oncol 2020, 38.

317. Valpione S., Carlino M.S., Mangana J., Mooradian M.J., McArthur G., Schadendorf D., Hauschild A., Menzies A.M., Arance A., Ascierto P.A. et al: Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. Eur J Cancer 2018, 91: 116 - 124.

318. Schreuer M., Jansen Y., Planken S., Chevolet I., Seremet T., Kruse V., Neyns B.: Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol 2017, 18(4): 464 - 472.

319. Scholtens A., Geukes Foppen M.H., Blank C.U., van Thienen J.V., van Tinteren H., Haanen J.B.: Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression. Eur J Cancer 2015, 51(5): 642 - 652.

320. Postow M.A., Chesney J., Pavlick A.C., Robert C., Grossmann K., McDermott D., Linette G.P., Meyer N., Giguere J.K., Agarwala S.S. et al: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015, 372(21): 2006 - 2017.

321. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S. et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369(2): 134 - 144.

322. Ugurel S., Hildenbrand R., Zimpfer A., La Rosee P., Paschka P., Sucker A., Keikavoussi P., Becker J.C., Rittgen W., Hochhaus A. et al: Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005, 92(8): 1398 - 1405.

323. Wyman K., Atkins M.B., Prieto V., Eton O., McDermott D.F., Hubbard F., Byrnes C., Sanders K., Sosman J.A.: Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006, 106(9): 2005 - 2011.

324. D'Angelo S.P., Larkin J., Sosman J.A., Lebbe C., Brady B., Neyns B., Schmidt H., Hassel J.C., Hodi F.S., Lorigan P. et al: Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. J Clin Oncol 2017, 35(2): 226 - 235.

325. Shoushtari A.N., Munhoz R.R., Kuk D., Ott P.A., Johnson D.B., Tsai K.K., Rapisuwon S., Eroglu Z., Sullivan R.J., Luke J.J. et al: The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer 2016, 122(21): 3354 - 3362.

326. Weichenthal M., Ugurel S., Leiter U.M., Satzger I., Kahler K.C., Welzel J., Pfohler C., Feldmann-Boddeker I., Meier F.E., Terheyden P. et al: Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry. Journal of Clinical Oncology 2019, 37(15_suppl): 9505 - 9505.

327. Weber J.S., Gibney G., Sullivan R.J., Sosman J.A., Slingluff C.L., Jr., Lawrence D.P., Logan T.F., Schuchter L.M., Nair S., Fecher L. et al: Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 2016, 17(7): 943 - 955.

328. Reschke R., Ziemer M.: Rechallenge with checkpoint inhibitors in metastatic melanoma. J Dtsch Dermatol Ges 2020, 18(5): 429 - 436.

329. Wolchok J.D., Hoos A., O'Day S., Weber J.S., Hamid O., Lebbe C., Maio M., Binder M., Bohnsack O., Nichol G. et al: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15(23): 7412 - 7420.

330. Nishino M., Giobbie-Hurder A., Gargano M., Suda M., Ramaiya N.H., Hodi F.S.: Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 2013, 19(14): 3936 - 3943.

331. Martinez S.R., Young S.E.: A rational surgical approach to the treatment of distant melanoma metastases. Cancer Treat Rev 2008, 34(7): 614 - 620.

332. Sosman J.A., Moon J., Tuthill R.J., Warneke J.A., Vetto J.T., Redman B.G., Liu P.Y., Unger J.M., Flaherty L.E., Sondak V.K.: A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer 2011, 117(20): 4740 - 4706.

333. Howard J.H., Thompson J.F., Mozzillo N., Nieweg O.E., Hoekstra H.J., Roses D.F., Sondak V.K., Reintgen D.S., Kashani-Sabet M., Karakousis C.P. et al: Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol 2012, 19(8): 2547 - 2555.

334. Blankenstein S.E., Aarts MJB., van den Berkmortel F., Boers-Sonderen M., van den Eertwegh AJM., Franken M.G., de Groot J.W., Haanen JBAG, Hospers G., Kapiteijn E. et al: Surgery for unresectable stage IIIC and IV melanoma in the era of new systemic therapy. J Clin Oncol 2020, 38.

335. Leung A.M., Hari D.M., Morton D.L.: Surgery for distant melanoma metastasis. Cancer J 2012, 18(2): 176 - 184.

336. Creech O., Jr., Ryan R.F., Krementz E.T.: Treatment of melanoma by isolation-perfusion technique. J Am Med Assoc 1959, 169(4): 339 - 343.

337. Thompson J.F., Lai D.T., Ingvar C., Kam P.C.: Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 1994, 4 Suppl 1: 45 - 50.

338. Moreno-Ramirez D., de la Cruz-Merino L., Ferrandiz L., Villegas-Portero R., Nieto-Garcia A.: Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist 2010, 15(4): 416 - 427.

339. Cornett W.R., McCall L.M., Petersen R.P., Ross M.I., Briele H.A., Noyes R.D., Sussman J.J., Kraybill W.G., Kane J.M., 3rd, Alexander H.R. et al: Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006, 24(25): 4196 - 4201.

340. Hyde M.A., Hadley M.L., Tristani-Firouzi P., Goldgar D., Bowen G.M.: A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. Arch Dermatol 2012, 148(5): 592 - 596.

341. Cotter M.A., McKenna J.K., Bowen G.M.: Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg 2008, 34(2): 147 - 151.

342. Naylor M.F., Crowson N., Kuwahara R., Teague K., Garcia C., Mackinnis C., Haque R., Odom C., Jankey C., Cornelison R.L.: Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003, 149 Suppl 66: 66 - 70.

343. Youland R.S., Blanchard M.L., Dronca R., Kottschade L., Markovic S.N., Olivier K.R., Park S.S.: Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era. Clin Transl Radiat Oncol 2017, 6: 25 - 30.

344. Seegenschmiedt M.H., Keilholz L., Altendorf-Hofmann A., Urban A., Schell H., Hohenberger W., Sauer R.: Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 1999, 44(3): 607 - 618.

345. McQuay H.J., Collins S.L., Carroll D., Moore R.A.: Radiotherapy for the palliation of painful bone metastases. The Cochrane database of systematic reviews 2000(2): CD001793.

346. Liew D.N., Kano H., Kondziolka D., Mathieu D., Niranjan A., Flickinger J.C., Kirkwood J.M., Tarhini A., Moschos S., Lunsford L.D.: Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg 2011, 114(3): 769 - 779.

347. Atkins M.B., Sosman J.A., Agarwala S., Logan T., Clark J.I., Ernstoff M.S., Lawson D., Dutcher J.P., Weiss G., Curti B. et al: Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 2008, 113(8): 2139 - 2145.

348. Tawbi H.A., Forsyth P.A., Algazi A., Hamid O., Hodi F.S., Moschos S.J., Khushalani N.I., Lewis K., Lao C.D., Postow M.A. et al: Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med 2018, 379(8): 722 - 730.

349. Komori T., Otsuka A., Kusuba N., Taniguchi K., Endo Y., Honda T., Kabashima K.: Rapid regression of metastatic brain tumours in a melanoma patient after dabrafenib/trametinib therapy. Eur J Dermatol 2017, 27(5): 548 - 549.

350. Davies M.A., Saiag P., Robert C., Grob J.J., Flaherty K.T., Arance A., Chiarion-Sileni V., Thomas L., Lesimple T., Mortier L. et al: Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 2017, 18(7): 863 - 873.

351. Kroeze S.G., Fritz C., Hoyer M., Lo S.S., Ricardi U., Sahgal A., Stahel R., Stupp R., Guckenberger M.: Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. Cancer Treat Rev 2017, 53: 25 - 37.

352. Anker C.J., Ribas A., Grossmann A.H., Chen X., Narra K.K., Akerley W., Andtbacka R.H., Noyes R.D., Shrieve D.C., Grossmann K.F.: Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 2013, 31(17): e283 - 287.

353. Anker C.J., Grossmann K.F., Atkins M.B., Suneja G., Tarhini A.A., Kirkwood J.M.: Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys 2016, 95(2): 632 - 646.

354. Bang A., Wilhite T.J., Pike LRG., Cagney D.N., Aizer A.A., Taylor A., Spektor A., Krishnan M., Ott P.A., Balboni T.A. et al: Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys 2017, 98(2): 344 - 351.

355. Trapani S., Manicone M., Sikokis A., D'Abbiero N., Salaroli F., Ceccon G., Buti S.: Effectiveness and safety of "real" concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review. Crit Rev Oncol Hematol 2019, 142: 9 - 15.

356. Tsui J.M., Mihalcioiu C., Cury F.L.: Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab. Cureus 2018, 10(2): e2238.

357. Bei D., Osawa M., Uemura S., Ohno T., Gobburu J., Roy A., Hasegawa M.: Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers. Cancer Sci 2020, 111(2): 528 - 535.

358. Bianconi C., Gandini G., Zanotti G., Dall'Ara M., Sterzi E., Barbazza R., Marini P.: 3PC-020 Nivolumab weight-based dosing vs flat dose economic analysis. European Journal of Hospital Pharmacy 2019, 26(Suppl 1): A45 - A46.

359. Schadendorf D., Hassel J.C., Fluck M., Eigentler T., Loquai C., Berneburg M., Gutzmer R., Meier F., Mohr P., Hauschild A. et al: Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED), LBA67. Ann Oncol 2019, 30(suppl. 5): 903 - 904.

360. Millen A.E., Tucker M.A., Hartge P., Halpern A., Elder D.E., Guerry Dt., Holly E.A., Sagebiel R.W., Potischman N.: Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev 2004, 13(6): 1042 - 1051.

361. Silver J.K., Baima J.: Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013, 92(8): 715 - 727.

362. Nilsson H., Angeras U., Bock D., Borjesson M., Onerup A., Fagevik Olsen M., Gellerstedt M., Haglind E., Angenete E.: Is preoperative physical activity related to post-surgery recovery? A cohort study of patients with breast cancer. BMJ open 2016, 6(1): e007997.

363. Siegel G.W., Biermann J.S., Chugh R., Jacobson J.A., Lucas D., Feng M., Chang A.C., Smith S.R., Wong S.L., Hasen J.: The multidisciplinary management of bone and soft tissue sarcoma: an essential organizational framework. J Multidiscip Healthc 2015, 8: 109 - 115.

364. Shehadeh A., El Dahleh M., Salem A., Sarhan Y., Sultan I., Henshaw R.M., Aboulafia A.J.: Standardization of rehabilitation after limb salvage surgery for sarcomas improves patients" outcome. Hematol Oncol Stem Cell Ther 2013, 6(3-4): 105 - 111.

365. Cox C.L., Montgomery M., Oeffinger K.C., Leisenring W., Zeltzer L., Whitton J.A., Mertens A.C., Hudson M.M., Robison L.L.: Promoting physical activity in childhood cancer survivors: results from the Childhood Cancer Survivor Study. Cancer 2009, 115(3): 642 - 654.

366. Field T.: Massage therapy research review. Complement Ther Clin Pract 2016, 24: 19 - 31.

367. Tantawy S.A., Abdelbasset W.K., Nambi G., Kamel D.M.: Comparative Study Between the Effects of Kinesio Taping and Pressure Garment on Secondary Upper Extremity Lymphedema and Quality of Life Following Mastectomy: A Randomized Controlled Trial. Integr Cancer Ther 2019, 18: 1534735419847276.

368. Fallon M., Giusti R., Aielli F., Hoskin P., Rolke R., Sharma M., Ripamonti C.I., Committee E.G.: Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol 2018, 29(Suppl 4): iv166 - iv191.

369. Oren R., Zagury Al., Katzir O., Kollender Y., Meller I.: Musculoskeletal Cancer Surgery. In., edn. Edited by Malawer. Dordrecht: Springer; 2013: 583 - 593.

370. Committee. NMA: Topic: The Diagnosis and Treatment of Lymphedema. Position Statement of the National Lymphedema Network. In.; 2011: 1 - 19.

371. Baxter G.D., Liu L., Petrich S., Gisselman A.S., Chapple C., Anders J.J., Tumilty S.: Low level laser therapy (Photobiomodulation therapy) for breast cancer-related lymphedema: a systematic review. BMC Cancer 2017, 17(1): 833.

372. Segal R., Zwaal C., Green E., Tomasone J.R., Loblaw A., Petrella T., Exercise for People with Cancer Guideline Development G: Exercise for people with cancer: a systematic review. Curr Oncol 2017, 24(4): e290 - e315.

373. Boyd C., Crawford C., Paat C.F., Price A., Xenakis L., Zhang W., Evidence for Massage Therapy Working G: The Impact of Massage Therapy on Function in Pain Populations-A Systematic Review and Meta-Analysis of Randomized Controlled Trials: Part II, Cancer Pain Populations. Pain Med 2016, 17(8): 1553 - 1568.

374. Stout N.L., Baima J., Swisher A.K., Winters-Stone K.M., Welsh J.: A Systematic Review of Exercise Systematic Reviews in the Cancer Literature (2005 - 2017). PM R 2017, 9(9S2): S347 - S384.

375. Hu M., Lin W.: Effects of exercise training on red blood cell production: implications for anemia. Acta Haematol 2012, 127(3): 156 - 164.

376. Bland K.A., Zadravec K., Landry T., Weller S., Meyers L., Campbell K.L.: Impact of exercise on chemotherapy completion rate: A systematic review of the evidence and recommendations for future exercise oncology research. Crit Rev Oncol Hematol 2019, 136: 79 - 85.

377. Mustian K.M., Alfano C.M., Heckler C., Kleckner A.S., Kleckner I.R., Leach C.R., Mohr D., Palesh O.G., Peppone L.J., Piper B.F. et al: Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis. JAMA Oncol 2017, 3(7): 961 - 968.

378. Kinkead B., Schettler P.J., Larson E.R., Carroll D., Sharenko M., Nettles J., Edwards S.A., Miller A.H., Torres M.A., Dunlop B.W. et al: Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Cancer 2018, 124(3): 546 - 554.

379. Streckmann F., Zopf E.M., Lehmann H.C., May K., Rizza J., Zimmer P., Gollhofer A., Bloch W., Baumann F.T.: Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014, 44(9): 1289 - 1304.

380. Kleckner I.R., Kamen C., Gewandter J.S., Mohile N.A., Heckler C.E., Culakova E., Fung C., Janelsins M.C., Asare M., Lin P.J. et al: Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018, 26(4): 1019 - 1028.

381. Lee J.M., Look R.M., Turner C., Gardiner S.K., Wagie T., Douglas J., Sorenson L., Evans L., Kirchner S., Dashkoff C. et al: Low-level laser therapy for chemotherapy-induced peripheral neuropathy. Journal of Clinical Oncology 2012, 30(15_suppl): 9019 - 9019.

382. Rick O., von Hehn U., Mikus E., Dertinger H., Geiger G.: Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics 2017, 38(2): 85 - 94.

383. Kilinc M., Livanelioglu A., Yildirim S.A., Tan E.: Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med 2014, 46(5): 454 - 460.

384. Oberoi S., Zamperlini-Netto G., Beyene J., Treister N.S., Sung L.: Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 2014, 9(9): e107418.

385. Ross M., Fischer-Cartlidge E: Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia. Clin J Oncol Nurs 2017, 21(2): 226 - 233.

386. Kessels E., Husson O., van der Feltz-Cornelis C.M.: The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis. Neuropsychiatr Dis Treat 2018, 14: 479 - 494.

387. Rief H., Omlor G, Akbar M., Welzel T., Bruckner T., Rieken S., Haefner M.F, Schlampp I., Gioules A., Habermehl D. et al: Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy - first results of a randomized pilot trial. BMC Cancer 2014, 14: 67.

388. Bensadoun R.J., Nair R.G.: Low-Level Laser Therapy in the Management of Mucositis and Dermatitis Induced by Cancer Therapy. Photomed Laser Surg 2015, 33(10): 487 - 491.

389. Temoshok L.: Biopsychosocial studies on cutaneous malignant melanoma: psychosocial factors associated with prognostic indicators, progression, psychophysiology and tumor-host response. Soc Sci Med 1985, 20(8): 833 - 840.

390. Dirksen S.R.: Perceived well-being in malignant melanoma survivors. Oncol Nurs Forum 1989, 16(3): 353 - 358.

391. Lichtenthal W.G., Cruess D.G., Schuchter L.M., Ming M.E.: Psychosocial factors related to the correspondence of recipient and provider perceptions of social support among patients diagnosed with or at risk for malignant melanoma. J Health Psychol 2003, 8(6): 705 - 719.

392. Sollner W., Zschocke I., Zingg-Schir M., Stein B., Rumpold G., Fritsch P., Augustin M.: Interactive patterns of social support and individual coping strategies in melanoma patients and their correlations with adjustment to illness. Psychosomatics 1999, 40(3): 239 - 250.

393. Devine D., Parker P.A., Fouladi R.T., Cohen L.: The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment. Psychooncology 2003, 12(5): 453 - 462.

394. Folkman S., Lazarus R.S., Gruen R.J., DeLongis A.: Appraisal, coping, health status, and psychological symptoms. J Pers Soc Psychol 1986, 50(3): 571 - 579.

395. Беляев А.М., Чулкова В.А., Семиглазова Т.Ю., Рогачев М.В. (eds.): Онкопсихология для врачей-онкологов и медицинских психологов. Руководство. СПб: Любавич; 2017.

396. Fawzy F.I., Cousins N., Fawzy N.W., Kemeny M.E., Elashoff R., Morton D.: A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance. Arch Gen Psychiatry 1990, 47(8): 720 - 725.

397. Holland J.C., Passik S., Kash K.M., Russak S.M., Gronert M.K., Sison A., Lederberg M., Fox B., Baider L.: The role of religious and spiritual beliefs in coping with malignant melanoma. Psychooncology 1999, 8(1): 14 - 26.

398. Baider L., Perry S., Sison A., Holland J., Uziely B., DeNour A.K.: The role of psychological variables in a group of melanoma patients. An Israeli sample. Psychosomatics 1997, 38(1): 45 - 53.

399. Lehto U.S., Ojanen M., Kellokumpu-Lehtinen P.: Predictors of quality of life in newly diagnosed melanoma and breast cancer patients. Ann Oncol 2005, 16(5): 805 - 816.

400. Fawzy F.I., Fawzy N.W., Hyun C.S., Elashoff R., Guthrie D., Fahey J.L., Morton D.L.: Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 1993, 50(9): 681 - 689.

401. Fawzy F.I., Kemeny M.E., Fawzy N.W., Elashoff R., Morton D., Cousins N., Fahey J.L.: A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures. Arch Gen Psychiatry 1990, 47(8): 729 - 735.

402. Fawzy F.I., Canada A.L., Fawzy N.W.: Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up. Arch Gen Psychiatry 2003, 60(1): 100 - 103.

403. Boesen E.H., Boesen S.H., Frederiksen K., Ross L., Dahlstrom K., Schmidt G., Naested J., Krag C., Johansen C.: Survival after a psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol 2007, 25(36): 5698 - 5703.

404. Boesen E.H., Ross L., Frederiksen K., Thomsen B.L., Dahlstrom K., Schmidt G., Naested J., Krag C., Johansen C.: Psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol 2005, 23(6): 1270 - 1277.

405. McLoone J., Menzies S., Meiser B., Mann G.J., Kasparian N.A.: Psycho-educational interventions for melanoma survivors: a systematic review. Psychooncology 2013, 22(7): 1444 - 1456.

406. Sample A., He Y.Y.: Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed 2018, 34(1): 13 - 24.

407. Craig S., Earnshaw C.H., Viros A.: Ultraviolet light and melanoma. J Pathol 2018, 244(5): 578 - 585.

408. Runger T.M.: Mechanisms of Melanoma Promotion by Ultraviolet Radiation. J Invest Dermatol 2016, 136(9): 1751 - 1752.

409. Green A.C., Williams G.M., Logan V., Strutton G.M.: Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011, 29(3): 257 - 263.

410. Ghiasvand R., Weiderpass E., Green A.C., Lund E., Veierod M.B.: Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study. J Clin Oncol 2016, 34(33): 3976 - 3983.

411. Dessinioti C., Geller A.C., Stergiopoulou A., Swetter S.M., Baltas E., Mayer J.E., Johnson T.M., Talaganis J., Trakatelli M., Tsoutsos D. et al: Association of Skin Examination Behaviors and Thinner Nodular vs Superficial Spreading Melanoma at Diagnosis. JAMA Dermatol 2018, 154(5): 544 - 553.

412. Kasparian N.A., Branstrom R., Chang Y.M., Affleck P., Aspinwall L.G., Tibben A., Azizi E., Baron-Epel O., Battistuzzi L., Bruno W. et al: Skin examination behavior: the role of melanoma history, skin type, psychosocial factors, and region of residence in determining clinical and self-conducted skin examination. Arch Dermatol 2012, 148(10): 1142 - 1151.

413. Titus L.J., Clough-Gorr K., Mackenzie T.A., Perry A., Spencer S.K., Weiss J., Abrahams-Gessel S., Ernstoff M.S.: Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth. Br J Dermatol 2013, 168(3): 571 - 576.

414. Pflugfelder A., Kochs C., Blum A., Capellaro M., Czeschik C., Dettenborn T., Dill D., Dippel E., Eigentler T., Feyer P. et al: Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". J Dtsch Dermatol Ges 2013, 11 Suppl 6: 1 - 116, 111 - 126.

415. DeRose E.R., Pleet A., Wang W., Seery V.J., Lee M.Y., Renzi S., Sullivan R.J., Atkins M.B.: Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma. Melanoma Res 2011, 21(4): 364 - 369.

416. Schneider J.: The teaspoon rule of applying sunscreen. Arch Dermatol 2002, 138(6): 838 - 839.

417. Karnofsky D.A., Burchenal J.H.: The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of chemotherapeutic agents. edn. Edited by MacLeod C. New York: Columbia University Press; 1949: 191 - 205.

418. Гомболевский В.А., Лайпан А.Ш., Шапиев А.Н., Владзимирский А.В., Морозов С.П. (eds.): Методические рекомендации по применению критериев ответа солидных опухолей на химиотерапевтическое лечение (RECIST 1.1). Методические рекомендации N 46; 2018.